NORINYL 1+35 21-DAY
LOE ApproachingNDAORAL-21TABLET
Approved
Dec 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 14h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NORINYL 1+35 21-DAY is an oral contraceptive tablet containing norethindrone and ethinyl estradiol, approved in 1974 for prevention of pregnancy. This combination hormonal contraceptive works by suppressing ovulation through progestin and estrogen activity. It is a foundational product in the oral contraceptive market with over 50 years of clinical use.
LOE Approaching
As a legacy oral contraceptive approaching loss of exclusivity, this product is likely experiencing portfolio rationalization with focus shifting to newer formulations and extended-cycle regimens.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on NORINYL 1+35 offers limited career growth opportunity given its mature, declining lifecycle stage and minimal linked job postings. Roles are primarily defensive, focused on market maintenance, generic competition mitigation, and portfolio optimization rather than innovation or expansion.
Brand ManagerProduct Manager
Worked on NORINYL 1+35 21-DAY at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.